Oxford Biomedica Plc is a biopharmaceutical company, which engages in the research and development of gene and cell therapy. The firm also provides bioprocessing and process development services to third parties. It operates through following segments: Platform and Product. The Platform segment consists of the revenue generating bioprocessing and process development activities undertaken for third parties. The Product segment includes clinical and preclinical development of in vivo and ex vivo gene and cell therapy products which are owned by the group. The company was founded by Alan J. Kingsman and Susan M. Kingsman in 1995 and is headquartered in Oxford, the United Kingdom.
Oxford BioMedica plc stock price
Today's LON:OXB chart, history & news
|Year to date change||35.23%|
About Oxford BioMedica plc
|Entity name||Report date||Shares held|
Aggregated insiders summary data for the last 6 months.
|Full name||Reported title||Total bought||Total sold||Net transacted|
|Full name||Reported title||Effective date||Amount of shares||Price per share||Total cost|
Oxford BioMedica plc dividends
|Ex date||Payment date||Record date||Declared date||Amount||Description||Frequency|
Oxford Biomedica (LON: OXB) published its financial results for the fiscal first half on Thursday that highlighted a 6% annualised growth in its revenue to £34 million. In the same period last year, it had recorded a lower £32.1 million of revenue. The gene and cell therapy company said it generated £23.4 million of revenue from bioprocessing and commercial development segment in the first half that concluded on 30th June versus the year-ago figu...
Another turbulent week in financial markets is behind us. The European Central Bank (ECB) left its key rates unchanged but made some changes to its GDP forecasts. On the vaccine front, AstraZeneca was forced to halt its COVID-19 testing as one patient unexpectedly fell ill. ECB unchanged The ECB held its regular meeting on Thursday where it decided to leave the deposit facility rate unchanged at -0.50. It also left the main interest rate un...
Shares of Oxford Biomedica (LON: OXB) have been trading in a volatile manner in the past two days after its partner AstraZeneca said it had to pause COVID-19 vaccine trial testing. Fundamental analysis: AZN eliminated from a race? A major drugmaker AstraZeneca, and Oxford University, reported that their coronavirus vaccine trial has been paused, raising concerns among investors over how the halt might affect the supply deal between the two compan...